Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Brooklyn ImmunoTherapeutics, Inc. (BTX)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
0.5172-0.0112 (-2.12%)
At close: 04:00PM EDT
0.5211 +0.00 (+0.75%)
After hours: 06:00PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Intermediate-term KST

Intermediate-term KST

Previous Close0.5284
Open0.5399
Bid0.5089 x 1000
Ask0.5375 x 800
Day's Range0.5000 - 0.5597
52 Week Range0.4500 - 13.6300
Volume1,098,737
Avg. Volume601,975
Market Cap29.723M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.8250
Earnings DateApr 15, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for BTX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Brooklyn ImmunoTherapeutics, In
    Analyst Report: Warner Bros. Discovery, Inc.Warner Bros. Discovery, the result of combining two large media firms, is one of the largest media firms in the world with tremendous scale and reach. The new company owns some of the biggest global networks including HBO, Discovery, CNN, and TLC and well-known franchises like Superman, Rick and Morty, and Game of Thrones. The firm’s content production studios include Warner Bros., HBO, Discovery Studios, DC Films, and Cartoon Network Studios. The company operates two major streaming services, HBO Max and Discovery+.
    Rating
    Fair Value
    Economic Moat
    3 days agoMorningstar
View more
  • Benzinga

    Brooklyn ImmunoTherapeutics Shares Tick lower After Data From Head and Neck Cancer Study

    Brooklyn ImmunoTherapeutics Inc (NASDAQ: BTX) has announced results from the INSPIRE Phase 2 trial of IRX-2 in patients with newly diagnosed stage II, III, or IVA squamous cell carcinoma of the oral cavity. The study's primary endpoint was to estimate 2-year Event-Free Survival (EFS) with key secondary endpoints of Overall Survival (OS) and safety of IRX-2. 150 patients were enrolled in the study. At two years of follow-up in the intention-to-treat (n=105) population, the median EFS was 48.3 mon

  • GlobeNewswire

    Brooklyn ImmunoTherapeutics Announces Results of Phase 2 Study of IRX-2 in Head and Neck Cancer

    SAN DIEGO, July 26, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq:BTX) (“Brooklyn” or the “Company”) today announces results from the INSPIRE phase 2 trial of IRX-2, a multi-cytokine biologic immunotherapy, in patients with newly diagnosed stage II, III, or IVA squamous cell carcinoma of the oral cavity. The primary endpoint of the study was to estimate 2-year Event-Free Survival (EFS) with key secondary endpoints of Overall Survival (OS) and safety of IRX-2. One hundred and

  • GlobeNewswire

    Brooklyn ImmunoTherapeutics Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

    SAN DIEGO, June 17, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq:BTX) (“Brooklyn” or the “Company”), a biopharmaceutical company focused on developing advanced therapies using state-of-the-art mRNA cell engineering technology, today announced that on June 17, 2022, it received a notice (the “Notice”) from the Nasdaq Stock Market LLC (“Nasdaq”), stating that the Company is not in compliance with the minimum bid price requirement ("Minimum Bid Requirement") of US$1.00 per sha

Advertisement
Advertisement